Intravenous immunoglobulins control scleromyxoedema

Annals of the Rheumatic Diseases

Volumn 61, Issue 1, 2002, Pages 59-61

  Righi, A ^a   Schiavon, F ^b   Jablonska, S ^c   Doria, A ^b   Blasczyk, M ^c   Rondinone, R ^b   Todesco, S ^b   Matucci Cerinic, M ^a  

^a Division of Rheumatology   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Klinika Dermatogiczna   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETAMETHASONE; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIMETHYL SULFOXIDE; GLYCOSAMINOGLYCAN; IMMUNOGLOBULIN; ISOTRETINOIN; MELPHALAN;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; HUMAN; MALE; MUCINOSIS; MYXEDEMA; PRIORITY JOURNAL; SCLERODERMA; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0036145088     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.1.59     Document Type: Article

References (12)

1. Fatal scleromyxedema: Report of a case and review of the literature
2. Scleromyxedema associated with non-Hodgkin lymphoma
3. Myeloma associated scleromyxedema with extensive involvement of small bowel
4. Arndt Gottron scleromyxedema. Summary of 2 years treatment
5. Scleromyxedema
6. Spontaneous resolution of lichen myxoedematosus
7. Immunomodulatory effect of immunoglobulins
8. Scleromyxedema: Response to high dose intravenous immunoglobulin (hdlVIg)
9. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin - A preliminary report
10. High dose intravenous immunoglobulin therapy for rheumatic disease: Clinical relevance and personal experience
11. Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy
12. Mechanism of intravenous immune globulin therapy in antibody mediated autoimmune diseases